ATAI Life Sciences B.V. IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on ATAI Life Sciences B.V., and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| ATAI Life Sciences B.V. | ATAI - NASDAQ |
$13.00-$15.00 | $15.00 | $21.00 | 15 million | 6/18/2021 |
| Credit Suisse, Citigroup, Cowen, Berenberg | ||||||
Co-Manager(s): Cantor, RBC, Canaccord Genuity
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-04-20 Terms Added 2021-06-11 | ||||||
ATAI Life Sciences B.V. Quote & Chart - Click for current quote - ATAI
IPO Boutique aggregates information on public companies and private companies, such as "ATAI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About ATAI Life Sciences B.V. (adapted from ATAI Life Sciences B.V. prospectus):
They are a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ATAI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.